Nearly a quarter of the world’s population may not have access to a COVID-19 vaccine until at least 2022, warns a study published by The BMJ today.
A second study estimates that 3.7 billion adults worldwide are willing to have a COVID-19 vaccine, highlighting the importance of designing fair and equitable strategies to ensure that supply can meet demand, especially in low and middle income countries.
Taken together, these findings suggest that the operational challenges of the global COVID-19 vaccination program will be at least as difficult as the scientific challenges associated with their development.
In the first study, researchers from the Johns Hopkins Bloomberg School of Public Health analyzed pre-orders for COVID-19 vaccines ahead of their regulatory approval that had been publicly announced by countries around the world.
By November 15, 2020, several countries had reserved a total of 7.48 billion doses, or 3.76 billion courses from 13 manufacturers, out of 48 COVID-19 vaccine candidates in clinical trials.
Just over half (51%) of these doses will go to high income countries, which represent 14% of the world’s population, say the authors. Low and middle income countries will potentially have the remainder, despite these countries comprising more than 85% of the world’s population.
If all of these vaccine candidates were successfully scaled, the total projected manufacturing capacity would be 5.96 billion courses by the end of 2021, with prices ranging from $6.00 (£4.50; €4.90) per course to as high as $74 per course.
Up to 40% of the vaccine courses from these vaccine manufacturers might potentially remain for low- and middle-income countries. However, this will depend, in part, on how high-income countries share what they procure and whether the US and Russia participate in globally coordinated efforts.
But the authors point out that even if all of these vaccine manufacturers were to succeed in reaching their maximum production capacity, at least a fifth of the world’s population would not have access to vaccines until 2022.
“This study provides an overview of how high-income countries have secured future supplies of covid-19 vaccines, but that access for the rest of the world is uncertain,” they write. “Governments and manufacturers might provide much-needed assurances for equitable allocation of covid-19 vaccines through greater transparency and accountability over these arrangements.”
In the second study, researchers based in China and the US estimated target populations for whom vaccines would be required, to help guide development of fair and equitable allocation strategies across the globe.
They find that target population sizes for covid-19 vaccination vary widely by geographical region, vaccine objectives (such as maintaining essential core services, reducing severe covid-19, and stopping virus transmission), and the impact of vaccine hesitancy in reducing demand.
They point to evidence suggesting that around 68% of the global population (3.7 billion adults) is willing to receive a covid-19 vaccine, and say their findings “provide an evidence base for global, regional, and national vaccine prioritization and allocation.”
“Variations in the size of the target populations within and between regions emphasize the tenuous balance between vaccine demand and supply, especially in low and middle income countries without sufficient capacity to meet domestic demand for covid-19 vaccine” they conclude.
Both studies are observational, and the authors acknowledge the implications of uncertainty and incomplete information for their analyses.
Nevertheless, these findings illustrate the considerable scale and complexity of manufacturing, purchasing, distributing, and administering covid-19 vaccines in a way that meets global needs, and does so equitably among nations and populations.
In a linked editorial, Jason Schwartz at Yale School of Public Health points out that many countries have already shown a commitment to equitable global access to covid-19 vaccines by purchasing through the COVAX Facility — an initiative that invests part of the payment in vaccines for poorer countries.
But he says vigilance is required “to ensure that such aspirations are realized in the months and years ahead.”
He argues that the successful, equitable implementation of covid-19 vaccination programs “requires unprecedented global coordination and a sustained commitment of resources — financial, logistical, and technical — from high-income countries.”
In particular, he says US participation in vaccination efforts “will be invaluable in ensuring that all populations globally have access to the covid-19 vaccines that will ultimately help bring an end to this devastating global health crisis.”
“Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis” by Anthony D So and Joshua Woo, 15 December 2020, The BMJ.
“Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study” by Wei Wang, Qianhui Wu, Juan Yang, Kaige Dong, Xinghui Chen, Xufang Bai, Xinhua Chen, Zhiyuan Chen, Cécile Viboud, Marco Ajelli and Hongjie Yu, 15 December 2020, The BMJ.
“Equitable global access to coronavirus disease 2019 vaccines – Vaccines will be as challenging to deliver as they were to develop” by Jason L Schwartz, 15 December 2020, The BMJ.